top of page
HOME
ABOUT US
SOCIAL IMPACT
STRATEGY
GENE THERAPY
CELL THERAPY
RNA-BASED THERAPY
TARGETED THERAPIES
MICROBIOME
TEAM
PORTFOLIO
CURRENT PORTFOLIO
PAST PORTFOLIO
NEWSROOM
CONTACT
More
Use tab to navigate through the menu items.
NEWSROOM
4BIO Capital jointly leads $25 million Series A financing of ViaNautis Bio
Nov 13, 2023
Araris Biotech AG Announces Research Collaboration with Taiho Pharmaceutical
Nov 9, 2023
SparingVision named a ‘Fierce 15’ Company by Fierce Biotech
Aug 29, 2023
Cell and gene therapy manufacturing: the next generation of startups
Jun 26, 2023
4BIO Capital Portfolio Company Ray Therapeutics Closes Oversubscribed $100M Series A Financing
May 16, 2023
4BIO Capital Participates in $130M Funding of New Gene and Cell Manufacturing Specialist Ascend
May 9, 2023
1
2
3
4
5
ARCHIVE
March 2025
(1)
1 post
January 2025
(1)
1 post
November 2024
(3)
3 posts
October 2024
(3)
3 posts
May 2024
(1)
1 post
April 2024
(1)
1 post
March 2024
(1)
1 post
January 2024
(1)
1 post
November 2023
(2)
2 posts
August 2023
(1)
1 post
June 2023
(1)
1 post
May 2023
(2)
2 posts
December 2022
(2)
2 posts
November 2022
(1)
1 post
October 2022
(1)
1 post
September 2022
(2)
2 posts
June 2022
(2)
2 posts
April 2022
(1)
1 post
March 2022
(1)
1 post
February 2022
(1)
1 post
SEARCH BY TAGS
portfolio
(27)
27 posts
4BIO Ventures II
(20)
20 posts
investment
(10)
10 posts
appointment
(8)
8 posts
collaboration
(8)
8 posts
4BIO Ventures III
(6)
6 posts
Orchard Therapeutics
(6)
6 posts
SparingVision
(6)
6 posts
acquisition
(5)
5 posts
advisory board
(4)
4 posts
approval
(4)
4 posts
Araris
(4)
4 posts
publication
(4)
4 posts
Ascend
(3)
3 posts
CodeBio
(3)
3 posts
Ray Therapeutics
(3)
3 posts
Spark Therapeutics
(3)
3 posts
Takeda
(3)
3 posts
ViaNautis
(3)
3 posts
AAV
(2)
2 posts
ADC Therapeutics
(2)
2 posts
Carisma
(2)
2 posts
IPO
(2)
2 posts
Kyowa Kirin
(2)
2 posts
Redpin Therapeutics
(2)
2 posts
review
(2)
2 posts
TiGenix
(2)
2 posts
4BATLE
(1)
1 post
AI
(1)
1 post
AMED
(1)
1 post
awards
(1)
1 post
BLA
(1)
1 post
Chugai
(1)
1 post
clinical trials
(1)
1 post
DBJ
(1)
1 post
EBV
(1)
1 post
EGLS
(1)
1 post
Eli Lilly
(1)
1 post
Entact
(1)
1 post
ETF
(1)
1 post
exit
(1)
1 post
Fierce 15
(1)
1 post
grant
(1)
1 post
Harbor Capital
(1)
1 post
Hornet Therapeutics
(1)
1 post
IND
(1)
1 post
Insig AI
(1)
1 post
Intellia
(1)
1 post
Luca Science
(1)
1 post
March Bio
(1)
1 post
merger
(1)
1 post
Moderna
(1)
1 post
pricing
(1)
1 post
results
(1)
1 post
Taiho
(1)
1 post
Trogenix
(1)
1 post
venture
(1)
1 post
FOLLOW US
bottom of page
